BioLineRx (NASDAQ:BLRX) Posts Earnings Results, Beats Expectations By $0.07 EPS

BioLineRx (NASDAQ:BLRX) released its earnings results on Thursday. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The business had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the previous year, the firm earned ($0.09) earnings per share.

BioLineRx Trading Up 0.9 %

Shares of BLRX opened at $1.12 on Friday. The business’s 50-day moving average price is $1.20 and its 200-day moving average price is $1.46. BioLineRx has a twelve month low of $0.81 and a twelve month high of $2.53. The stock has a market cap of $81.13 million, a PE ratio of -1.24 and a beta of 1.40. The company has a quick ratio of 1.86, a current ratio of 1.53 and a debt-to-equity ratio of 0.50.

Analysts Set New Price Targets

A number of research firms have recently commented on BLRX. StockNews.com upgraded BioLineRx to a “sell” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Tuesday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BLRX. Renaissance Technologies LLC grew its holdings in shares of BioLineRx by 278.0% during the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new position in shares of BioLineRx during the first quarter worth about $178,000. Envestnet Asset Management Inc. purchased a new position in shares of BioLineRx during the first quarter worth about $88,000. Finally, LPL Financial LLC grew its holdings in shares of BioLineRx by 152.7% during the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 71,134 shares in the last quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.